TNFSF13B and myeloid sarcoma: Further supporting a protective role of BAFF in MS are findings from clinical trials of Atacicept, which was administered to extend the time between relapses but increased the relapse frequency in the intervention group, even though mature B cell numbers and serum Ig concentrations decreased significantly (23).